Protective effect of dihydromyricetin revents fatty liver through nuclear factor‑κB/p53/B‑cell lymphoma 2‑associated X protein signaling pathways in a rat model

Guo,Lu; Zhang,Haifeng; Yan,Xiuping

doi:10.3892/mmr.2018.9783

Protective effect of dihydromyricetin revents fatty liver through nuclear factor‑κB/p53/B‑cell lymphoma 2‑associated X protein signaling pathways in a rat model

Authors:
- Lu Guo
- Haifeng Zhang
- Xiuping Yan
View Affiliations

Affiliations: Department of Hepatopathy, Sixth People's Hospital of Qingdao, Qingdao, Shandong 266033, P.R. China
Published online on: December 20, 2018 https://doi.org/10.3892/mmr.2018.9783
Pages: 1638-1644
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dihydromyricetin is the major flavonoid in vine tea, whose pharmacological action has attracted increasing attention in recent years. The triglyceride, albumin (ALB), alanine aminotransferase, aspartate aminotransferase, malondialdehyde, superoxide dismutase, glutathione (GSH), GSH peroxidase, tumor necrosis factor‑α, interleukin (IL)‑1β, IL‑6 and IL‑18 expression levels were measured using enzyme‑linked immunosorbent assay kits. The protein levels of ALB and collagen I, PPARα, NF‑κB, p53 and Bax were used to measure using western blotting. The results revealed that dihydromyricetin prevented the development of fatty liver, and inhibited oxidative stress, inflammation and apoptosis in a fatty liver rat model. In addition, treatment with dihydromyricetin inhibited the levels of ALB and collagen I, while it induced peroxisome proliferator‑activated receptor α protein expression. Dihydromyricetin also suppressed the protein expression levels of nuclear factor (NF)‑κB, p53 and B‑cell lymphoma 2‑associated X protein (Bax) in the rat model. Collectively, it is concluded that dihydromyricetin exerted a protective effect on fatty liver through NF‑κB/p53/Bax signaling pathways in a rat model.

View Figures

View References

1	Song Q, Liu L, Yu J, Zhang J, Xu M, Sun L, Luo H, Feng Z and Meng G: Dihydromyricetin attenuated Ang II induced cardiac fibroblasts proliferation related to inhibitory of oxidative stress. Eur J Pharmacol. 807:159–167. 2017. View Article : Google Scholar : PubMed/NCBI
2	Huang H, Hu M, Zhao R, Li P and Li M: Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway. Oncol Rep. 30:2467–2475. 2013. View Article : Google Scholar : PubMed/NCBI
3	Rotman Y: Similarity between studies of dihydromyricetin and reservatrol for NAFLD. Pharmacol Res. 100:3352015. View Article : Google Scholar : PubMed/NCBI
4	Houghton D, Thoma C, Hallsworth K, Cassidy S, Hardy T, Burt AD, Tiniakos D, Hollingsworth KG, Taylor R, Day CP, et al: Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 15:96–102.e3. 2017. View Article : Google Scholar : PubMed/NCBI
5	Alexander KS, Zakai NA, Lidofsky SD, Callas PW, Judd SE, Tracy RP and Cushman M: Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The reasons for geographic and racial differences in stroke cohort. PLoS One. 13:e01941532018. View Article : Google Scholar : PubMed/NCBI
6	Kim W, Kim BG, Lee JS, Lee CK, Yeon JE, Chang MS, Kim JH, Kim H, Yi S, Lee J, et al: Randomised clinical trial: The efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 45:1073–1083. 2017. View Article : Google Scholar : PubMed/NCBI
7	Li L, Hai J, Li Z, Zhang Y, Peng H, Li K and Weng X: Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 63:166–173. 2014. View Article : Google Scholar : PubMed/NCBI
8	Bu W and Luo T: miR-1297 promotes cell proliferation of non-small cell lung cancer cells: Involving in PTEN/Akt/Skp2 signaling pathway. DNA Cell Biol. 36:976–982. 2017. View Article : Google Scholar : PubMed/NCBI
9	Chan DC, Watts GF, Gan S, Wong AT, Ooi EM and Barrett PH: Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity. Arterioscler Thromb Vasc Biol. 30:1043–1050. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kalinowski P, Paluszkiewicz R, Ziarkiewicz-Wroblewska B, Wróblewski T, Remiszewski P, Grodzicki M and Krawczyk M: Liver function in patients with nonalcoholic fatty liver disease randomized to Roux-en-Y gastric bypass versus sleeve gastrectomy: A secondary analysis of a randomized clinical trial. Ann Surg. 266:738–745. 2017. View Article : Google Scholar : PubMed/NCBI
11	Gonzalez-Manan D, D'Espessailles A, Dossi CG, San Martin M, Mancilla RA and Tapia GS: Rosa mosqueta oil prevents oxidative stress and inflammation through the upregulation of PPAR-α and NRF2 in C57BL/6J rat fed a high-fat diet. J Nutr. 147:579–588. 2017. View Article : Google Scholar : PubMed/NCBI
12	Mukai T, Egawa M, Takeuchi T, Yamashita H and Kusudo T: Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in rat with nonalcoholic fatty liver disease. FEBS Open Bio. 7:1009–1016. 2017. View Article : Google Scholar : PubMed/NCBI
13	Sharifi N, Amani R, Hajiani E and Cheraghian B: Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine. 47:70–80. 2014. View Article : Google Scholar : PubMed/NCBI
14	Zhou Y, Ding YL, Zhang JL, Zhang P, Wang JQ and Li ZH: Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism. Biomed Pharmacother. 97:1397–1408. 2018. View Article : Google Scholar : PubMed/NCBI
15	Chen Y, Lv L, Pi H, Qin W, Chen J, Guo D, Lin J, Chi X, Jiang Z, Yang H and Jiang Y: Dihydromyricetin protects against liver ischemia/reperfusion induced apoptosis via activation of FOXO3a-mediated autophagy. Oncotarget. 7:76508–76522. 2016.PubMed/NCBI
16	Willy JA, Young SK, Stevens JL, Masuoka HC and Wek RC: CHOP links endoplasmic reticulum stress to NF-κB activation in the pathogenesis of nonalcoholic steatohepatitis. Mol Biol Cell. 26:2190–2204. 2015. View Article : Google Scholar : PubMed/NCBI
17	Shankar E, Zhang A, Franco D and Gupta S: Betulinic acid-mediated apoptosis in human prostate cancer cells involves p53 and nuclear Factor-kappa B (NF-κB) Pathways. Molecules. 22(pii): E2642017. View Article : Google Scholar : PubMed/NCBI
18	Zhang H, Tan X, Yang D, Lu J, Liu B, Baiyun R and Zhang Z: Dietary luteolin attenuates chronic liver injury induced by mercuric chloride via the Nrf2/NF-κB/P53 signaling pathway in rats. Oncotarget. 8:40982–40993. 2017.PubMed/NCBI
19	Zhou DZ, Sun HY, Yue JQ, Peng Y, Chen YM and Zhong ZJ: Dihydromyricetin induces apoptosis and cytoprotective autophagy through ROS-NF-κB signalling in human melanoma cells. Free Radic Res. 51:517–528. 2017. View Article : Google Scholar : PubMed/NCBI
20	Kim JY, Song EH, Lee HJ, Oh YK, Choi KH, Yu DY, Park SI, Seong JK and Kim WH: HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. J Mol Biol. 397:917–931. 2010. View Article : Google Scholar : PubMed/NCBI
21	Maraslioglu M, Weber R, Korff S, Blattner C, Nauck C, Henrich D, Jobin C, Marzi I and Lehnert M: Activation of NF-κB after chronic ethanol intake and haemorrhagic shock/resuscitation in rat. Br J Pharmacol. 170:506–518. 2013. View Article : Google Scholar : PubMed/NCBI